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Previous studies have evaluated the role of miRNAs in cancer initiation and progression. MiR-34a was found to be downregu-
lated in several tumors, including medulloblastomas. Here we employed targeted transgenesis to analyze the function of miR-
34a in vivo. We generated mice with a constitutive deletion of the miR-34a gene. These mice were devoid of mir-34a expres-
sion in all analyzed tissues, but were viable and fertile. A comprehensive standardized phenotypic analysis including more
than 300 single parameters revealed no apparent phenotype. Analysis of miR-34a expression in human medulloblastomas and
medulloblastoma cell lines revealed significantly lower levels than in normal human cerebellum. Re-expression of miR-34a in
human medulloblastoma cells reduced cell viability and proliferation, induced apoptosis and downregulated the miR-34a tar-
get genes, MYCN and SIRT1. Activation of the Shh pathway by targeting SmoA1 transgene overexpression causes medulloblas-
toma in mice, which is dependent on the presence and upregulation of Mycn. Analysis of miR-34a in medulloblastomas
derived from ND2:SmoA1(tg) mice revealed significant suppression of miR-34a compared to normal cerebellum. Tumor inci-
dence was significantly increased and tumor formation was significantly accelerated in mice transgenic for SmoA1 and lacking
miR-34a. Interestingly, Mycn and Sirt1 were strongly expressed in medulloblastomas derived from these mice. We here dem-
onstrate that miR-34a is dispensable for normal development, but that its loss accelerates medulloblastomagenesis. Strat-
egies aiming to re-express miR-34a in tumors could, therefore, represent an efficient therapeutic option.
MicroRNAs (miRNAs) are a class of small endogenous RNAs
that inhibit translation or initiate degradation of target
mRNAs by sequence-speciﬁc interaction. They are involved
in regulating important functions in development and differ-
entiation, including cell cycle control and apoptosis.1,2 Previ-
ous studies have evaluated the role of miRNAs in cancer
initiation and progression.3–5 Not only are miRNAs differen-
tially expressed in tumors as compared with normal tissues,
but also in the primary tumor.6 Several reports point to the
fact that miR-34a is frequently deleted or absent in human
cancers, including medulloblastomas.7–10 In mice, miR-34a is
ubiquitously expressed, with the highest levels occurring in
the brain.11 MiR-34a is a direct target of the tumor suppres-
sor p53, and ectopic miR-34a expression inhibits invasion
and migration and induces apoptosis, senescence and cell
cycle arrest.10,12–15. These p53-mediated effects are due to the
repression of speciﬁc targets, including MYCN, SIRT1, E2F3,
cyclin D1, DLL1, CDK4/6, cyclin E2, MET and
BCL2.10,14,16–18 However, it was most recently reported that
mice deﬁcient for miR-34a and/or its homolog, miR-34b/c,
present no obvious phenotype.19–21 In contrast to what was
expected, miR-34a deﬁciency also did not accelerate lym-
phoma formation in Em-Myc mice.20,21
Medulloblastoma is the most common malignant and
highly invasive embryonal brain tumor in childhood.22 In
children, medulloblastoma occurs at any age, and histological
as well as molecular variants are associated with progno-
sis.23–26 Despite multimodal therapy, one-third of patients
with medulloblastoma succumb to the disease and survivors
often suffer from treatment-related side-effects, including
neurocognitive deﬁcits related to craniospinal irradiation.27,28
Medulloblastomas arise either from a population of cells that
have self-renewal capacity and the potential to differentiate in cells
of all neuronal lineages, such as neural stem cells,29,30 or from
granule cell progenitors (GNPs).31 MYCN drives the proliferation
of GNPs during normal cerebellar development and during
medulloblastomagenesis.31–33 MYCN ampliﬁcation or overexpres-
sion occurs in Sonic hedgehog signaling activated (Shh) medullo-
blastomas, whileMYC is frequently ampliﬁed or overexpressed in
Group 3 medulloblastomas, which are often associated with large
cell anaplastic (LCA) or classical pathologies.34 MYCN overex-
pression in GNPs from transgenic mice induced aggressive medul-
loblastoma with LCA histology.35 These ﬁndings indicate that
MYCN can drive medulloblastoma independently of Shh and
could play an important role in medulloblastoma initiation.
The speciﬁc role of miRNAs in medulloblastoma pathoge-
nesis has not been completely elucidated to date, although
differential expression patterns in normal cerebellum and
medulloblastomas, as well between different medulloblastoma
subgroups have been reported.36,37 Both the MYCN-regulated
mir-17–92 cluster,37,38 and coexpressed miR-182 and miR-
183 were shown to play an oncogenic role in medulloblas-
toma,36,39 by increasing proliferation and dissemination. In
contrast, miR-34a has been reported to have a tumor sup-
pressive function by downregulating MAGE antigens or pro-
teins involved in NOTCH signaling in medulloblastoma.40,41
What’s new?
MicroRNAs (miRNAs) play an important role in cancer initiation and progression. An miRNA called “miR-34a” is downregulated
in a variety of human cancers. In this study, the authors found that miR-34a acts as a tumor suppressor in genetically engi-
neered mice, and that it appears to regulate medulloblastoma formation in vivo. Restoring expression of miR-34a in medullo-
blastomas or other human cancers with deregulated miR-34a might, therefore, be a promising therapeutic strategy.
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However, the role of miR-34 in the initiation and progression
of medulloblastoma in vivo or its effect on MYCN expression
in medulloblastoma cells has not yet been investigated.
MYCN is a direct target of miR-34a and could be an ini-
tiator of medulloblastomagenesis. We investigated the role of
miR-34a in medulloblastoma tumor biology in vitro and in
vivo by re-expressing miR-34a in medulloblastoma cell lines
and analyzing the relevance of this tumor suppressive
miRNA for medulloblastoma progression by cell viability, cell
proliferation and apoptosis. We generated miR-34a knockout
mice to assess the physiological role of the miR-34a during
development and in the adult organism. To further character-
ize the importance and the function of miR-34a during
tumor initiation and progression, we crossbred the miR-34a
knockout mice with the well-established ND2:SmoA1(tg)
mice with a penetrance for developing medulloblastoma. Our
Figure 1..
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results indicate a relevant role of miR-34a as a regulator of
medulloblastoma formation.
Material and Methods
Generation of miR-34a mutant mice
The transgenic miR-34a knockout mouse was generated as
previously described42,43 and is outlined in Figure 1a
(Taconic Artemis, Cologne, Germany). The targeting vec-
tor was derived from a C57Bl/6 bacterial artiﬁcial chromo-
some clone that includes the miR-34a gene. The ﬁrst loxP
site and the F3-ﬂanked selection marker (Puro) were
inserted in nonconserved sequence at about 0.8 kb
upstream of the mir-34a gene. The second loxP site and
the FRT-ﬂanked Neomycin cassette (Neo) were inserted in
a nonconserved sequence stretch at about 0.4 kb down-
stream of miR-34a. A counterselection cassette encoding
thymidine kinase (TK) was inserted at the 30 end of the
vector. C57Bl/6N embryonic stem cells (ESCs) were elec-
troporated and selected on d5 after electroporation by
adding G418 (positive selection) and gancyclovir (negative
selection) and by adding puromycin on d2. Correct
recombination events were veriﬁed by Southern blot analy-
sis of genomic DNA digested with BglII, AﬂII and HpaI,
using both internal and external probes. The targeting
strategy allowed generation of conditional and constitutive
knockout alleles. After Flp-mediated removal of selection
markers, the conditional knockout allele was generated.
Crossing mice carrying mir-34aﬂ/ﬂ to mice ubiquitously
expressing Cre recombinase generated a miR-34a constitu-
tive (conv) allele in which the mir-34a gene is deleted.
Mouse genotyping was performed by PCR on tail tips
using PCR Mix (Peqlab) as shown in Figure 1b. Speciﬁc
detection of the miR-34a conv allele was achieved using
the primers, CTTCAGCCATCCTGTTGAGG and
CTTCAGGCAGAGTTGCATGG. Mouse experiments were
carried out in accordance with the German Animal Wel-
fare Act and approved by the local animal ethics
committees.
Phenotyping of mice
The primary cohort for the phenotyping screen consisted of
36 miR-34a knockout mice and 37 wildtype control litter-
mates. All animals were analyzed in the German Mouse
Clinic (GMC) for signs of dysmorphology, behavioural and
neurological peculiarities, eye properties, nociception, energy
metabolism, clinical chemistry, immunology, allergy, steroid
metabolism, cardiovascular and lung function and pathology.
In addition, molecular proﬁling of selected organs was per-
formed. The general setup of these standardized screens was
previously described.44 A secondary cohort was analyzed to
conﬁrm ﬁndings observed in the primary screen. In this sec-
ond cohort, approximately half of the control animals were
littermates of the mutants, as in the primary screen cohort,
and the other half was substituted by independently bred
control animals of the same genetic background. Most males
of the secondary cohort were single-housed in contrast to the
primary cohort, in which most males were group-housed.
Breeding of SmoA1-transgenic mice
Genotyping of the ND2:SmoA1(tg) mice was performed as
described previously.45 No crossbreeding of two mice trans-
genic for the ND2:SmoA1(tg) allele was allowed, ensuring
that all ND2:SmoA1(tg) mice used in this study were hemi-
zygous for the ND2:SmoA1 allele.
Histological analysis
Organs were ﬁxed in 4% neutral buffered formalin for at
least 24 hr. For histology, 4 mm sections were cut from paraf-
ﬁn blocks and stained with hematoxylin and eosin (H&E).
Pictures were taken using the NanoZoomer 2.0HT (Hama-
matsu Photonics Deutschland GmbH, Herrsching am
Ammersee, Germany).
Nucleic acid isolation
DNA was isolated using the DNeasy Blood & Tissue Kit
(Qiagen) according to the manufacturer’s instructions.
Figure 1. Generation and phenotypic analysis of miR-34a knockout mice. (a) Schematic representation of the miR-34a targeting construct.
The first loxP site and the F3-flanked selection marker (Puro) have been inserted in a nonconserved sequence region 0.8 kb upstream of
miR-34a. The second loxP site and the FRT-flanked neomycin cassette have been inserted a nonconserved sequence region at 0.4 kb
downstream of miR-34a. The TK expression cassette is inserted downstream of the target as a negative selection marker. The targeting
strategy allows generation of conditional and constitutive knockout alleles. After Flp-mediated removal of the selection marker the condi-
tional ko allele is generated. In vivo Cre-mediated deletion of miR-34a resulted in the constitutive ko allele. (b) PCR of mouse genomic DNA
from miR-34a homozygous mice (ko), wildtype mice (wt) and heterozygous mice (ko/wt). A single 257 bp fragment is indicative of miR-34a
ko mice, a single 1379 bp fragment indicates wildtype, while both fragments are detectable in heterozygous mice (M, marker). (c) Detection
of miR-34a deficiency in various organs. RT-qPCR was performed on RNA extracted from miR-34ako/wt, miR-34ako/ko and wildtype brains,
lungs, livers and spleens. RT-qPCR confirmed gene dose-dependent miR-34a expression in all organs. The loss of genetic information for
miR-34a in the homozygous knockout consequently led to a complete loss of miR-34a expression. Data were normalized to RNU6B expres-
sion. (wt, wildtype; ko/wt, heterozygous; ko/ko, homozygous). (d) Hematoxylin-eosin (H&E) staining of various organs from wildtype, heter-
ozygous and homozygous miR-34a deficient mice. H&E stained histological slides of coronal sections of brain, ovary, testis, kidney and
lung revealed no difference in the organ histology between the wildtype control animals and the miR-34a mutants. Magnifications: brain,
testis52.53; ovary, kidney, lung553. H&E staining was performed on sagittal sections of heart and coronal sections of liver, spleen, thy-
mus and pancreas. No difference in the organ histology between control and mutant animals was detected. Magnifications: liver5103;
heart, spleen, thymus, pancreas5 53.
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Gene expression analysis
Total RNAs from ﬁve human nonmalignant cerebellar sam-
ples derived from adult donors (age range 21–29 years) were
purchased from Biocat [Human Adult Normal Tissue Total
RNA-Brain-Cerebellum(Cat#: R1234040-10-3(5)-BC); Biocat
GmbH, Heidelberg]. The primary medulloblastoma tumors
used for the miRNA analysis (n5 21) were collected from
the initial biopsies at diagnosis and selected from the local
tumor bank in Essen and from the tumor bank of the Ger-
man Society for Pediatric Oncology and Hematology. The
tumor subgroup information for the histopathological sub-
grouping is listed in Supporting Information Table 3. MiRNA
was isolated from cells or primary medulloblastomas or nor-
mal cerebellum samples using the miRNeasyVR Micro Kit
(Qiagen), and cDNA reversetranscribed by miScript Reverse
Transcription Kit (Qiagen). Real-time PCR was performed
using the StepOnePlus real-time PCR system (Applied Bio-
systems) with SYBR Green PCR Master Mix (Applied Biosys-
tems) according to the manufacturer’s instructions.
Expression of human miR-34a (Qiagen, assay no.
MS00003318) and mouse miR-34a (Qiagen, assay no.
MS00001428) were normalized to RNU6B expression. Data
analysis and error propagation was performed using qbase-
PLUS software 1.5 (http://www.biogazelle.com).
Cell lines and cell culture
The ONS-76, HD-MB3, UW-228 and DAOY human medul-
loblastoma cell lines were grown in RPMI 1640 supplemented
with 10% FCS, L-glutamine and antibiotics, as described pre-
viously.46 Medium for HD-MB3 was also supplemented with
1% nonessential amino acids. The identity of all cell lines
was veriﬁed by the German Collection of Microorganisms
and Cell Cultures using STR genotyping (DSMZ, Braunsch-
weig, Germany).
Transient transfection of precursor miRNA
HiPerfect transfection reagent (Qiagen, Hilden, Germany)
was used to transiently transfect 250 ng of miExpress precur-
sor miRNA expression clones (Genecopoeia, Rockville, MD)
into medulloblastoma cell lines according to the manufac-
turer’s instructions.
Cell viability, proliferation and apoptosis analysis
One day before transfection, 4,000 cells were seeded in tripli-
cate into 96-well plates to permit surface adherence and then
transfected with 0.25-lg plasmid DNA. Cells were collected
after 120 hr for cell viability, proliferation and apoptosis
assays. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) cell viability assay was performed
according to the manufacture’s protocol (Roche, Penzberg,
Germany). Cell proliferation was analyzed using the BrdU
ELISA (Roche) and apoptosis was assessed using the Cell
Death ELISA (Roche), both performed according to the man-
ufacturer’s protocols.
Western blotting
Cell pellets and lysates were harvested according to standard
protocols. After blotting, membranes were blocked 1 hr with
5% nonfat dry milk in TBS-T0,1, and incubated with antibod-
ies against MYCN (Santa Cruz sc53993, 1:200) or SIRT1
(Cell Signaling #2310 and #2028, 1:1,000) overnight at 4C,
washed twice and then incubated 1 hr with horseraddish
peroxidase-conjugated (HRP) anti-rabbit IgG (GE Healthcare,
1:2,000, room temperature) or HRP anti-mouse IgG (GE
Healthcare NA9340V) at room temperature as previously
described.47 Proteins were visualized using the ECLplus west-
ern blotting detection kit (Amersham) and analyzed on a
FusionFX7 detection device (Vilber Lourmat, Eberhartzell,
Germany). GAPDH expression (a-GAPDH, Millipore) served
as a loading control.
Statistical analysis
A student’s two-sided t-test was used for the comparison of all inter-
val variables. GraphPad Prism 5.0 was used to perform Kaplan–
Meier survival analysis with log-rank statistics on mouse cohorts.
Results
Generation and phenotypic characterization of miR-34a
knockout mice
To model and to characterize the function of miR-34a in
vivo, we used targeted transgenesis in mice. Mice lacking the
miR-34a gene were generated by tetraploid blastocyst com-
plementation from the recombinant ES cells (Fig. 1a). Inter-
crossing of heterozygous mice produced homozygous miR-
34ako/ko offspring that were viable, fertile and obtained in the
expected Mendelian ratio (chi-square5 2.2, n5 149, p5 0.3).
The lifespan of the observed mice was 15–17 months. Mouse
genotypes were conﬁrmed using PCR speciﬁc for miR-34a
(Fig. 1b). We next aimed to analyze miR-34a mRNA expres-
sion in a panel of adult murine tissues from wildtype and
mutant mice. The expression levels of miR-34a in the differ-
ent organs derived from wildtype mice was highly variable. It
ranged from low expression in the lung up to very high
expression in the brain (Fig. 1c). Analysis of miR-34a tran-
script expression in the knockout mice conﬁrmed efﬁcient
silencing in all murine organs analyzed compared to miRNA
levels in the control mice (Fig. 1c). Expression of miR-34a
was dependent on zygosity, with virtually no detectable miR-
34 transcript expression in tissues from mice with constitu-
tive homozygous deletion of the miR-34a gene (Fig. 1c). To
determine the physiological role of miR-34a during develop-
ment and in the adult organism, a cohort of miR-34a knock-
out mice underwent a standardized and comprehensive
phenotypic analysis at the GMC. The analysis comprises sev-
eral hundred parameters to assess dysmorphology, behavior,
neurology, eye development and vision, nociception, energy
metabolism, clinical chemistry, immunology, allergy, steroid
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metabolism, cardiovascular analysis, lung function, molecular
phenotyping and pathology.44 This highly standardized analy-
sis enables the detection of phenotypes that would otherwise
not be detected, and also allows to exclude the presence of
phenotype abnormalities in case of negative results. In sum-
mary, no differences between miR-34a homozygous knockout
mice and their wildtype littermates were detected that could
be validated in secondary screens for the analyzed parame-
ters. Some differences were observed only in the primary
screens of neurological and behaviour parameters (results of
phenotyping summarized in Supporting Information Tables 1
and 2 and Supporting Information Figs. 1 and 2). No histo-
logical differences between the organs from miR-34a knock-
out mice and those from control animals (Figs. 1d and 1e)
were observed also in regard to the cerebellum, and no
increase in tumor incidence was observed in aged miR-34a
knockout mice. These results are in line with previous
reports.20,21 Taken together, miR-34a deﬁcient mice are
Figure 2. MiR-34a is expressed at low levels in medulloblastoma and its re-expression reduces viability of medulloblastoma cell lines. (a)
MiR-34a expression was analyzed in 21 medulloblastomas and five samples of normal cerebellum by RT-qPCR. MiR-34a expression levels
was significantly decreased in primary medulloblastomas. Data were normalized to RNU6B. (CB, cerebellum; MB, medulloblastoma). (b)
MiR-34a expression was analyzed in four human medulloblastoma cell lines. Mir-34a mRNA expression was reduced in medulloblastoma
cell lines in comparison to the control tissue. Data were normalized to RNU6B. (c) MiR-34a re-expression significantly reduced viability of
medulloblastoma cells in the MTT assay. scRNA5 scrambled RNA, **p<0.005, ***p<0.0005. (d) MiR-34a transfection of medulloblastoma
cells reduced proliferation after 120h using the BrdU ELISA, as compared to the controls scRNA. *p<0.05; **p<0.005, ***p<0.0005. (e)
Fractions of apoptotic cells were elevated in miR-34a transfected medulloblastoma cells using the Cell Death ELISA. *p<0.05;
***p<0.0005. (f) Western blotting for MYCN and SIRT1 of whole-cell lysates of medulloblastoma cell lines with and without miR-34a (miR)
re-expression confirmed reduced protein expression.
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viable, fertile and show no major phenotypic abnormalities
despite some behavioral and neurological changes.
The role of miR-34a in human medulloblastoma
To investigate and deﬁne the effects of miR-34a overexpres-
sion on tumor biology (cell viability, proliferation and apo-
ptosis) and on the expression of their targets, we ﬁrst
analyzed the miR-34a mRNA expression in 21 primary
medulloblastomas compared to ﬁve cerebellum samples (Fig.
2a). Tumor samples expressed threefold less miR-34a. We
also detected lower miR-34a expression in four medulloblas-
toma cell lines compared to normal cerebellum (Fig. 2b).
Because miR-34a is a putative tumor suppressor, we ﬁrst
assessed the effect of miR-34a re-expression on cell viability
and proliferation. We observed inhibition of cell growth (Fig.
2c) and proliferative capacity (Fig. 2d) in all four medullo-
blastoma cell lines after ectopic expression of miR-34a using
a pEZX-based plasmid (Genecopoeia). This effect was inde-
pendent of the presence of functional TP53, since TP53 is
mutated in DAOY (C242F) and UW-228 (T155N) medullo-
blastoma cell lines,48 while HD-MB3 and ONS-76 cells pos-
sess no inactivating p53 mutations, but the R72P SNP in
TP53, which affects neither TP53 expression nor function.49
Additionally, the fraction of apoptotic cells was signiﬁcantly
lower in nontransfected medulloblastoma cells than in cells
ectopically expressing miR-34a (Fig. 2e). In line with the pre-
viously published data and based on our results, we conclude
that miR-34a has tumor suppressive effects in vitro.
MiR-34a is involved in multiple tumor suppressive path-
ways by directly or indirectly inhibiting the expression of
numerous proteins. Therefore, and as further support of the
relevance of miR-34 in the formation and progression of
human medulloblastoma, we investigated the expression of
its downstream targets, SIRT1 and MYCN, on protein level
in medulloblastoma cell lines. SIRT1 and MYCN expression
were signiﬁcantly downregulated by enforced miR-34a
expression in all four medulloblastoma cell lines in contrast
to cells transfected with a control plasmid (Fig. 2f).
Taken together, we detected decreased miR-34a expression
in a panel of human medulloblastoma cell lines and in pri-
mary medulloblastomas. Furthermore, our results indicate
that miR-34a re-expression induces apoptosis while also
inhibiting proliferation of medulloblastoma cell lines.
Absence of miR-34a accelerates tumor formation in murine
medulloblastoma
As we found miR-34a expression to be downregulated in pri-
mary human medulloblastomas and in medulloblastoma cell
lines, we proceeded to address the impact of miR-34a expres-
sion on medulloblastoma tumorigenesis in a mouse model.
We used the established medulloblastoma model,
ND2:SmoA1 transgenic (tg) mice,45 which model the Shh
Figure 3. MiR-34a knockout accelerates tumor formation in a mouse model of medulloblastoma. (a) Expression of miR-34a was analyzed by
RT-qPCR in the cerebella from wildtype mice and non-tumor-bearing ND2:SmoA1(tg) mice, as well as in medulloblastomas that arose in
ND2:SmoA1(tg) mice. Data were normalized to RNU6B. (CB wildtype, cerebella from wildtype mice; CB SmoA1 (tg), cerebella from non-
tumor bearing ND2:SmoA1(tg) mice; MB SmoA1 (tg), medulloblastomas derived from ND2:SmoA1(tg) mice). (b) Kaplan-Meier analysis of
transgenic mice with the endpoint defined as detection of symptomatic appearance of medulloblastoma. Mice double-transgenic for
ND2:SmoA1(tg) and miR-34ako/wt (blue curve) or ND2:SmoA1(tg) and miR-34ako/ko (red curve) showed a significantly shorter time to tumor
formation than mice expressing the SmoA1 transgene alone (black curve). (c) Western blot of whole-tissue extracts from tumors arising in
ND2:SmoA1(tg) mice and ND2:SmoA1(tg);miR-34ako/wt or ND2:SmoA1(tg);miR-34ako/wt mice. Mycn and Sirt1 expression was strongly
increased in tumors derived from SmoA1;miR-34a double-transgenic mice. (wt/wt, tumor-bearing ND2:SmoA1(tg) mice; wt/ko, double-
transgenic ND2:SmoA1(tg);miR-34ako/wt mice; ko/ko, double transgenic ND2:SmoA1(tg);miR-34ako/ko mice). For each genotype, tumors
derived from two different mice are displayed. C
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medulloblastoma subtype. Mice hemizygous for the
ND2:SmoA1 allele start developing medulloblastomas at 4
months of age and at 8 months, 50% of all ND2:SmoA1(tg)
mice had to be sacriﬁced due to tumor burden (Fig. 3b).
The miR-34a levels in the tumor tissue of ND2:SmoA1(tg)
mice with established medulloblastomas were signiﬁcantly
lower than in the cerebella from wildtype mice (p< 0.0001)
or in the cerebella of nontumor-bearing ND2:SmoA1(tg)
mice (p< 0.0001) (Fig. 3a). To elucidate the function of miR-
34a on tumor formation and progression, we crossbred miR-
34a knockout mice with the ND2:SmoA1(tg) mice to produce
double-transgenic mice. To conﬁrm the efﬁcient knock-out of
miR-34a transcript expression in ND2:SmoA1(tg) mice with
miR-34a knock-out (ND2:SmoA1(tg);miR-34ako/wt and
ND2:SmoA1(tg);miR-34ako/ko), we analyzed miR-34a expres-
sion in these mice in comparison to miR-34a levels in the
ND2:SmoA1(tg) control mice (with wildtype miR-34a). In
ND2:SmoA1(tg);miR-34ako/ko mice, miR-34a expression was
virtually not detectable in neither cerebellum nor tumor tis-
sue. In cerebella derived from ND2:SmoA1(tg);miR-34ako/wt
mice, expression of miR-34a was signiﬁcant lower than in
cerebella derived from ND2:SmoA1(tg) control mice. Inter-
estingly, miR-34a was also not detectable in tumors derived
from ND2:SmoA1(tg);miR-34ako/wt mice.
Mice expressing the SmoA1 transgene and deﬁcient for
the miR-34a gene displayed signiﬁcantly accelerated medullo-
blastoma formation compared to mice expressing SmoA1
alone (p< 0.0014, Fig. 3b). Both tumor incidence and time to
tumor formation in double-transgenic mice were signiﬁcantly
different from mice expressing the SmoA1 transgene alone
(Table 1 and Supporting Information Fig. 4). To further
characterize the functional role of miR-34a as a regulator of
medulloblastoma formation, expression of the miR-34a target
genes, Sirt1 and Mycn, were analyzed in the resulting tumors.
Levels for both Sirt1 and Mycn proteins were elevated in
tumors from double-transgenic mice compared to tumors
from SmoA1 mice, and target protein expression levels were
associated with the miR-34a gene dosage in the mice (Fig.
3c). Taken together, our results indicate an important and
relevant role of miR-34a in medulloblastoma formation and
progression in vivo.
Discussion
In several tumor entities miRNAs are deregulated. A miRNA
can act as an oncogene by inhibiting the expression of a
tumor suppressor gene or as a tumor suppressor by inhibi-
ting the expression of an oncogene.4 Our analysis of miR-34a
expression in medulloblastoma cell lines and primary human
medulloblastoma showed a signiﬁcant downregulation of this
miRNA compared to normal cerebellar tissue, conﬁrming
previous ﬁndings that miR-34a is a prominent tumor-
suppressive miRNA, which is downregulated in different
tumors. The aim of our in vitro studies was to explore the
function of the miR-34a in medulloblastoma cell lines. Re-
expression of miR-34a, which was present only at low levels
in all human medulloblastoma cell lines analyzed, induced
apoptosis and reduced the viability and proliferative capacity
of the cells. These data conﬁrm previously published reports
of miR-34a tumor-suppressive functions detected in other
tumor entities12,13,50,51 and characterize the phenotypic effect
of miR-34a re-expression in medulloblastoma cells.40,41
Next, we analyzed miR-34a function in vivo by targeted
transgenesis in mice. For this purpose, we generated a transgenic
mouse strain harboring a deletion of the miR-34a gene and,
thus, lacking functional miR-34a. Using this strain, we compre-
hensively assessed the overall picture of miR-34a functionality in
adult mice. For this purpose, 80 mice underwent an extensive
standardized screen interrogating 300 physiological parame-
ters that revealed no major phenotypical abnormalities in the
miR-34a deﬁcient mice. This comprehensive screen, however,
revealed some neurological and behavioral changes in mutant
mice that have not been previously assessed or reported, includ-
ing a decrease in prepulse inhibition and the acoustic startle
response (Supporting Information Figs. 1 and 2). In a subse-
quent validation cohort these behavioral phenotypes could not
be reproduced, possibly due to the inclusion of nonlittermate
controls. Despite these putative behavioral and neurological
changes, miR-34a deﬁcient mice are viable, fertile and show no
major phenotypic abnormalities. Our results are in line with and
extend the previously reported work of Choi et al. and Concep-
cion et al.20,21 Choi et al. described the generation of a miR-34
knockout mice born with an expected Mendelian ratio and no
visible abnormalities in development or pathology. Overexpres-
sion of miR-34a, miR-34b and miR-34c in ESCs led to reduc-
tions in Nanog, Sox2 and Mycn expression. Vice versa, Choi
et al. showed that induced pluripotent stem cells deﬁcient in
miR-34a and miR-34b/c had elevated Mycn expression.21 Con-
cepcion et al. reported no hematopoietic abnormalities or abnor-
malities of the several organs that they analyzed histologically.20
It remains to be explored whether challenging the mice with
Table 1. observed mortality for the ND2:SmoA1 mouse line and the double transgenic ND2:SmoA1;miR-34a mouse lines
mouse line
Number of mice
Time (months)
tumor incidencedeveloping tumors up to 4 up to 8 up to 16
SmoA1 1/- 18 out of 47 2 11 18 38%
SmoA1;miR-34a ko/wt 36 out of 47 12 32 35 75%
SmoA1;miR-34a ko/ko 25 out of 31 8 22 25 81%
The total number of mice observed in each time period is given. Death in all cases was a result of tumor formation.
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different stimuli or aging alone might reveal phenotypic abnor-
malities resulting from the miR-34 knockout. Indeed, Boon
et al. found reduced age-associated decline in cardiac function
in miR-34a deﬁcient mice.19 Taken together, our comprehensive
phenotypic screen corroborates and extends previous reports
and strongly points to a nonessential role of miR-34a in normal
murine development.
One prominent target of miR-34a is the MYCN onco-
gene, which is ampliﬁed in 4–10% of medulloblastoma
patients.52 Overexpression of MYCN has been observed in
55–88% human medulloblastomas.53,54 MYCN is an
important and direct target of the Shh signaling pathway
promoting cell cycle progression in the developing cerebel-
lum. MYCN upregulation is observed in medulloblastomas
associated with activated Shh signaling55,56 and is corre-
lated with unfavorable outcome. Mycn is required for nor-
mal cerebellar development, but much less is known about
Mycn function in the mouse hindbrain. Numerous investi-
gators have studied the mechanisms how MYCN alters the
stages of medulloblastoma formation or progression using
different mouse models for medulloblastoma.33,57 Aberrant
activation of Mycn expression in the developing mouse
cerebellum initiates a variety of medulloblastomas, includ-
ing both classical and LC/A tumors.58 Hallahan et al.
developed the well-established mouse model,
ND2:SmoA1(tg). This model is based on activation of the
Shh pathway by transgenic expression of a constitutively
active form of smoothened in mouse cerebellar granule
neuron precursors. Transgene expression causes early cere-
bellar granule cell hyperproliferation and 50% incidence
of medulloblastoma formation.45 In these ND2:SmoA1(tg)
mice, medulloblastomas arise depending on the presence
and upregulation of Mycn.32 We detected a tumor speciﬁc
suppression of miR-34a in tumors arising in
ND2:SmoA1(tg) mice. Crossing of SmoA1 mice with miR-
34a knockout mice signiﬁcantly shortened the time to
tumor formation, increased tumor incidence and reduced
survival of double-transgenic ND2:SmoA1(tg);miR-34ako/ko
mice. Interestingly, Sirt1 and Mycn expression was inver-
sely correlated with miR-34a gene dosage in SmoA1-
induced tumors. As the highest miR-34a target gene levels
were observed in double transgenic ND2:SmoA1(tg);miR-
34ako/ko mice, miR-34a seems to act as a repressor of
oncogenes in a dose dependent manner. These results
implicate that miR-34a is involved in tumor incidence and
survival in the ND2:SmoA1(tg) medulloblastoma model,
and this is also reﬂected by increased expression of miR-
34a target genes with oncogenic functions.
The mechanism, by which miR-34a is downregulated
during the process of tumorigenesis in the
ND2:SmoA1(tg) model remains elusive. It is tempting to
speculate that activation of Shh-signaling pathway itself
downregulates miR-34a in a feedback loop. Indeed, Shh-
induced Gli1 has recently been shown to downregulate
p53 transcription,59 while Shh-induced MYCN could
inhibit p53 activity via induction of MDM2.60 Both
mechanisms reducing p53 activity would thereby impair
p53-driven miR-34a expression. An alternative explantion
for the loss of miR-34a expression in the course of
medulloblastoma development would be a selective pres-
sure favoring cells having gradually downregulated or
even silenced miR-34a not as a (direct) effect of Shh
signaling.
Here, we demonstrate that miR-34a deﬁciency accel-
erates tumor formation in genetically engineered mice,
thus, that miR-34a exerts a tumor-suppressive function
in vivo. This has been anticipated by many investigators
based on in vitro data, but is in contrast to a recent
report by Concepcion et al., who were unable to detect
an effect of miR-34 deﬁciency on lymphoma formation
in Em-Myc transgenic mice. Binding sites for miR-34a
are present in the 30-UTR of both MYCN and cMYC.
However, tumors in Em-Myc mice are driven by trans-
genic cMyc cDNA overexpression. The cMyc cDNA
expressed in the Em-Myc mice lacks the natural cMYC
30-UTR which harbors miRNA binding sites, and there-
fore is not regulated by miR-34a in the Em-Myc model.
If cMyc is a relevant target of miR-34 in lymphoma, as
MYCN/Mycn most likely is in medulloblastoma, the
missing effect of miR-34a on lymphoma development in
the Em-Myc model may have resulted from intrinsic
Em-Myc model properties, such as missing regulatory
miR-34a binding motifs in the ectopically expressed
Myc cDNA (Supporting Information Fig. 5). Thus, the
ﬁndings for lymphoma in addition to those described
here for medulloblastoma point to a tumor-suppressive
role of miR-34a by regulating myc family protein
expression.
The results presented here provide important clues
into the functional roles of miR-34a and its relation to
the mechanisms and oncogenic signaling pathways
involved in medulloblastoma formation. In most cases
multiple signaling pathways are simultaneously regulated
by modulation of a single miRNA. Thus, therapy target-
ing a speciﬁc miRNA may represent a more effective
cancer treatment option than the pharmacological elimi-
nation of a single gene function.61 Comprehensive
knowledge of the targets, the underlying mechanisms
and the estimation of the effects of miR-34 are of clini-
cal relevance for the assessment and prediction of possi-
ble side effects of miR-34a-based therapy. One advantage
of a miR-34a-based therapy in medulloblastoma is that
by overexpressing miR-34a, several targets and signaling
pathways can be inﬂuenced. Re-expressing miR-34a
could simultaneously downregulate several target genes,
including MYCN, SIRT1, NOTCH pathway genes21 and
MAGE,41 and signaling pathways that impede develop-
ment of resistance to therapy. Effective miR-34a re-
expression in human medulloblastoma cells in vivo using
adenovirus as a vehicle has already been demonstrated
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by de Antonellis et al.40 Thus, strategies aiming to re-
express miR-34a in tumors could be a promising and
effective therapeutic strategy for the future, not only
against medulloblastoma but also other tumor types.
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